TLSI Stock Forecast 2025-2026
Distance to TLSI Price Targets
TLSI Price Momentum
🤔 Considering Trisalus (TLSI)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest TLSI Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, TLSI has a bullish consensus with a median price target of $11.00 (ranging from $10.00 to $16.00). Currently trading at $5.26, the median forecast implies a 109.1% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Justin Walsh at JonesTrading, projecting a 204.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TLSI Analyst Ratings
TLSI Price Target Range
Latest TLSI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TLSI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 13, 2025 | Lake Street | Buy | Initiates | $10.00 | |
| Jan 24, 2025 | Roth MKM | Jason Wittes | Buy | Reiterates | $11.00 |
| Dec 17, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Initiates | $10.00 |
| Nov 15, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $11.00 |
| Nov 11, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $11.00 |
| Oct 25, 2024 | Northland Capital Markets | Carl Byrnes | Outperform | Initiates | $12.50 |
| Sep 16, 2024 | Oppenheimer | Suraj Kalia | Outperform | Initiates | $10.00 |
| Jun 27, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $12.00 |
| May 30, 2024 | Canaccord Genuity | William Plovanic | Buy | Initiates | $12.00 |
| May 10, 2024 | JonesTrading | Justin Walsh | Buy | Initiates | $16.00 |
TriSalus Life Sciences Inc. (TLSI) Competitors
The following stocks are similar to Trisalus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TriSalus Life Sciences Inc. (TLSI) Financial Data
TriSalus Life Sciences Inc. has a market capitalization of $160.39M with a P/E ratio of 0.1x. The company generates $26.89M in trailing twelve-month revenue with a -205.5% profit margin.
Revenue growth is +41.5% quarter-over-quarter, while maintaining an operating margin of -95.2% and return on equity of +244.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
TriSalus Life Sciences Inc. (TLSI) Business Model
About TriSalus Life Sciences Inc.
Develops innovative cancer therapies using unique technologies.
TriSalus Life Sciences generates revenue by developing and commercializing advanced biopharmaceuticals for cancer treatment. The company focuses on solid tumors and utilizes proprietary technologies, such as Pressure-Enabled Drug Delivery (PEDD), to enhance the effectiveness of immunotherapies and improve drug distribution directly into tumors.
TriSalus collaborates with research institutions and healthcare providers to advance its therapies from clinical trials to market. Its innovative approach aims to address significant challenges in cancer treatment, potentially transforming patient outcomes and contributing to the overall life sciences market.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
116
CEO
Ms. Mary T. Szela B.S.N., M.B.A.
Country
United States
IPO Year
2021
Website
trisaluslifesci.comTriSalus Life Sciences Inc. (TLSI) Latest News & Analysis
TriSalus Life Sciences (Nasdaq: TLSI) announced that its researchers received two JVIR Top Paper Awards, including the Editor's Award for Distinguished Laboratory Investigation, recognizing their work in tumor treatment.
TriSalus Life Sciences' recognition for research excellence boosts its credibility and may enhance investor confidence in its innovative therapies and future growth potential.
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
1 month agoTriSalus Life Sciences Inc. has requested a $10 million drawdown from a $50 million credit agreement with OrbiMed to support its solid tumor treatment technologies.
TriSalus Life Sciences' $10 million drawdown from a $50 million credit agreement indicates strong backing for its innovative cancer treatments, potentially boosting investor confidence and stock performance.
TriSalus Life Sciences Inc. (Nasdaq: TLSI) appointed William J. Valle and Dr. Gary B. Gordon to its Board of Directors to enhance its strategic direction in treating solid tumors.
The appointment of experienced industry leaders to TriSalus Life Sciences' board may enhance strategic direction and credibility, potentially boosting investor confidence and company performance.
TriSalus Life Sciences Inc. (Nasdaq: TLSI) reported preliminary unaudited revenue of approximately $8.3 million for Q4 and full year 2024, driven by its TriNav® Infusion System.
Preliminary revenue of $8.3 million from the TriNav® Infusion System signals potential growth and market interest, impacting investor sentiment and stock performance for TriSalus Life Sciences.
TriSalus Life Sciences (Nasdaq: TLSI) announced research showing its Pressure Enabled Drug Delivery (PEDD) method improves intraarterial delivery of treatment to liver tumors in a porcine model.
TriSalus's research on enhanced drug delivery for liver tumors could lead to improved treatment outcomes, potentially boosting its market position and attracting investor interest.
TriSalus Life Sciences reports a $2.4M net loss this quarter but aims for positive cash flow by 2025. The company is expanding its TriNav system amidst risks of low cash reserves.
TriSalus's focus on the TriNav system highlights its strategic pivot amid financial losses. Investors should weigh growth potential against cash risks and possible dilution from fundraising needs.
Frequently Asked Questions About TLSI Stock
What is TriSalus Life Sciences Inc.'s (TLSI) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, TriSalus Life Sciences Inc. (TLSI) has a median price target of $11.00. The highest price target is $16.00 and the lowest is $10.00.
Is TLSI stock a good investment in 2025?
According to current analyst ratings, TLSI has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TLSI stock?
Wall Street analysts predict TLSI stock could reach $11.00 in the next 12 months. This represents a 109.1% increase from the current price of $5.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is TriSalus Life Sciences Inc.'s business model?
TriSalus Life Sciences generates revenue by developing and commercializing advanced biopharmaceuticals for cancer treatment. The company focuses on solid tumors and utilizes proprietary technologies, such as Pressure-Enabled Drug Delivery (PEDD), to enhance the effectiveness of immunotherapies and improve drug distribution directly into tumors.
What is the highest forecasted price for TLSI TriSalus Life Sciences Inc.?
The highest price target for TLSI is $16.00 from Justin Walsh at JonesTrading, which represents a 204.2% increase from the current price of $5.26.
What is the lowest forecasted price for TLSI TriSalus Life Sciences Inc.?
Price targets from Wall Street analysts for TLSI are not currently available. The stock is trading at $5.26.
What is the overall TLSI consensus from analysts for TriSalus Life Sciences Inc.?
The overall analyst consensus for TLSI is bullish. Out of 7 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are TLSI stock price projections?
Stock price projections, including those for TriSalus Life Sciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
